KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $4.4 billion.

  • Regeneron Pharmaceuticals' Total Current Liabilities rose 1075.22% to $4.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.4 billion, marking a year-over-year increase of 1075.22%. This contributed to the annual value of $4.4 billion for FY2025, which is 1075.22% up from last year.
  • According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Total Current Liabilities is $4.4 billion, which was up 1075.22% from $4.4 billion recorded in Q3 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' Total Current Liabilities peaked at $4.4 billion during Q3 2025, and registered a low of $2.9 billion during Q3 2022.
  • Its 5-year average for Total Current Liabilities is $3.5 billion, with a median of $3.6 billion in 2024.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 5890.15% in 2021, then plummeted by 2249.38% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' Total Current Liabilities (Quarter) stood at $3.9 billion in 2021, then decreased by 20.12% to $3.1 billion in 2022, then increased by 8.98% to $3.4 billion in 2023, then rose by 15.22% to $3.9 billion in 2024, then rose by 10.75% to $4.4 billion in 2025.
  • Its last three reported values are $4.4 billion in Q4 2025, $4.4 billion for Q3 2025, and $3.7 billion during Q2 2025.